RESTON, Va., Aug. 18 /PRNewswire/ — The Mirixa Corporation is
pleased to announce that Kerr Drug has signed a licensing agreement
for MirixaEdge(SM), Mirixa’s clinical application that supports the
delivery of pharmacist-based patient care services, including
Medication Therapy Management (MTM). Awarded a grant to support
delivery of patient care services by community pharmacists, Kerr
will be offering MTM services to the City of Charleston, SC and
Charleston Water Works employees and will utilize MirixaEdge as the
technology platform for this effort.
(Logo: http://photos.prnewswire.com/prnh/20100818/SF51721LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20100818/SF51721LOGO)
Kerr evaluated a number of MTM platforms to support the grant
initiative. Central to the decision to partner with Mirixa was the
robustness of the MirixaEdge application functionality.
Rebecca W. Chater, RPh, MPH, FAPhA, Executive Vice President
for Kerr Drug feels the MirixaEdge software with its programmatic
approach to chronic disease management is in alignment with Kerr’s
focus on developing new clinical services. “In order to ensure
consistency of clinical service delivery across our pharmacies, we
need a tool like MirixaEdge to provide the framework for guiding an
interactive discussion between the pharmacist and the patient. The
MirixaEdge application has the right level of structure, along with
disease-specific inquiries, that will be of great benefit to our
customers and staff.”
Kerr Drug will utilize the Mirixa technology to track the
progress of employee medication regimens, to provide patient
educational information, and to report on outcomes achieved through
MTM service delivery. Kerr has established itself as a leader in
providing pharmacist-supervised patient care services and this
grant will hel
‘/>”/>
SOURCE
